



aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

November 9, 2023

Phase 3 EFZO-FIT™ study of efzofitimid in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024.

Phase 2 EFZO-CONNECT™ study of efzofitimid in SSc-ILD initiated patient dosing.

Ended the third quarter of 2023 with \$105.6 million in cash, cash equivalents and investments.

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.

“During the third quarter we made meaningful progress with our clinical development program for our lead therapeutic candidate, efzofitimid, in interstitial lung disease (ILD),” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We had a positive data and safety monitoring board (DSMB) review for our global pivotal Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD with high unmet medical need. This study continues to enroll in the U.S., Europe and Japan and based on current projections, we expect to complete enrollment in this study early in the second quarter of 2024. Additionally, we dosed the first patient in our Phase 2 EFZO-CONNECT™ study in patients with systemic sclerosis (SSc, or scleroderma)-related ILD (SSc-ILD), which is currently enrolling in the U.S.”

Third Quarter 2023 and Subsequent Period Highlights

- **Continued enrollment in the global pivotal Phase 3 EFZO-FIT™ study to evaluate the efficacy and safety of efzofitimid in patients with pulmonary sarcoidosis.** This is a randomized, double-blind, placebo-controlled, 52-week study consisting of three parallel cohorts randomized equally to either 3.0 mg/kg or 5.0 mg/kg of efzofitimid or placebo dosed intravenously monthly for a total of 12 doses. The study intends to enroll up to 264 subjects with pulmonary sarcoidosis. The study is open for enrollment at nearly all of the centers intended in the U.S., Europe and Japan and is expected to expand to include centers in Brazil. Based on current enrollment projections, the Company expects to complete enrollment in the study early in the second quarter of 2024.
- **Completed a positive DSMB review for the Phase 3 EFZO-FIT™ study.** Data from the pre-planned, interim analysis of safety and tolerability of efzofitimid in patients with pulmonary sarcoidosis, which included the evaluation of patients who completed treatment, was evaluated. There were no drug-related serious adverse events, consistent with prior studies. The DSMB assessed that the study could continue unmodified and that the drug does not pose any undue risk to the patient that warrants additional safety measures.
- **Dosed the first patient in the Phase 2 EFZO-CONNECT™ study to evaluate the efficacy, safety and tolerability of efzofitimid in patients with SSc-ILD.** This proof-of-concept study is a randomized, double-blind, placebo-controlled, 28-week study consisting of three parallel cohorts randomized 2:2:1 to either 270 mg or 450 mg of efzofitimid or placebo dosed intravenously monthly for a total of 6 doses. The study intends to enroll 25 patients at multiple centers in the U.S. The primary objective of the study is to evaluate the efficacy of multiple doses of intravenous efzofitimid on pulmonary, cutaneous and systemic manifestations in patients with SSc-ILD.
- **Peer-reviewed article for efzofitimid published in the journal *Frontiers in Pharmacology*.** The publication, titled, “Exposure-response analyses of efzofitimid in patients with pulmonary sarcoidosis,” highlights a positive exposure response demonstrated by efzofitimid across multiple clinically relevant endpoints in the Phase 1b/2a study in patients with pulmonary sarcoidosis.
- **Presented two posters for efzofitimid at the European Respiratory Society (ERS) International Congress 2023.** The posters presented new data from a pooled, post hoc analysis from the Phase 1b/2a study of efzofitimid in patients with pulmonary sarcoidosis that further demonstrates efficacy and findings that identify the expression of neuropilin-2 (NRP2), efzofitimid’s binding partner, in the skin of patients with SSc-ILD.
- **Poster for efzofitimid accepted for presentation at the upcoming American College of Rheumatology (ACR) Convergence 2023.** The conference is scheduled to take place November 10 – 15, 2023, in San Diego, CA. The poster presents new data demonstrating the effects of efzofitimid in preclinical models of rheumatoid arthritis (RA) and RA-associated lung fibrosis.
 - Poster 1322 – Efzofitimid, a First-in-Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models on Monday, November 13, 2023, from 9:00 a.m. to 11:00 a.m. PST.

Third Quarter 2023 Financial Highlights and Cash Position

Operating expenses:				
Research and development	\$ 10,319	\$ 9,867	\$ 29,538	\$ 27,898
General and administrative	2,649	3,625	9,775	10,556
Total operating expenses	<u>12,968</u>	<u>13,492</u>	<u>39,313</u>	<u>38,454</u>
Loss from operations	(12,615)	(13,492)	(38,960)	(38,454)
Total other income (expense), net	1,273	247	3,324	634
Consolidated net loss	<u>(11,342)</u>	<u>(13,245)</u>	<u>(35,636)</u>	<u>(37,820)</u>
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited	2	1	7	3
Net loss attributable to aTyr Pharma, Inc.	<u>\$ (11,340)</u>	<u>\$ (13,244)</u>	<u>\$ (35,629)</u>	<u>\$ (37,817)</u>
Net loss per share, basic and diluted	<u>\$ (0.20)</u>	<u>\$ (0.46)</u>	<u>\$ (0.69)</u>	<u>\$ (1.34)</u>
Shares used in computing net loss per share, basic and diluted	57,885,393	28,663,047	51,700,864	28,184,698

ATYR PHARMA INC.
Condensed Consolidated Balance Sheets
(in thousands)

	September 30, 2023	December 31, 2022
	(unaudited)	
Cash, cash equivalents, restricted cash and available-for-sale investments	\$ 105,582	\$ 69,311
Other receivables	2,087	11,775
Property and equipment, net	5,644	3,059
Operating lease, right-of-use assets	6,812	7,250
Financing lease, right-of-use assets	1,791	1,248
Prepaid expenses and other assets	3,153	3,143
Total assets	<u>\$ 125,069</u>	<u>\$ 95,786</u>
Accounts payable, accrued expenses and other liabilities	\$ 11,648	\$ 12,968
Current portion of operating lease liability	774	630
Current portion of financing lease liability	459	264
Long-term operating lease liability, net of current portion	12,548	9,633
Long-term financing lease liability, net of current portion	1,437	1,007
Total stockholders' equity	<u>98,203</u>	<u>71,284</u>
Total liabilities and stockholders' equity	<u>\$ 125,069</u>	<u>\$ 95,786</u>

Contact:

Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com

Source: aTyr Pharma, Inc.